



OPEN ACCESS

EDITED AND REVIEWED BY
Marie-Agnes Dragon-Durey,
Université Paris Cité, France

*CORRESPONDENCE
Guo-Qing Tang
✉ GuoQing.Tang@ucb.com

†PRESENT ADDRESSES
Ketki Dhamnaskar,
Nurix Therapeutics, San Francisco,
CA, United States
Michelle D. Hoarty,
Dyne Therapeutics, Waltham,
MA, United States
Douangson D. Vadysirisack,
Dianthus Therapeutics, Waltham,
MA, United States
Zhong Ma,
Mariana Oncology, Watertown,
MA, United States
Rohit Vyasamneni,
BioNTech SE, Cambridge,
MA, United States
Nanqun Zhu,
Avilar Therapeutics, Waltham,
MA, United States
Camil Sayegh,
Mitochondria Emotion Inc., Cambridge,
MA, United States
Alonso Ricardo,
Mariana Oncology, Watertown,
MA, United States

RECEIVED 23 August 2023
ACCEPTED 08 September 2023
PUBLISHED 25 September 2023

CITATION
Tang G-Q, Tang Y, Dhamnaskar K,
Hoarty MD, Vyasamneni R,
Vadysirisack DD, Ma Z, Zhu N, Wang J-G,
Bu C, Cong B, Palmer E, Duda PW,
Sayegh C and Ricardo A (2023)
Corrigendum: Zilucoplan, a macrocyclic
peptide inhibitor of human complement
component 5, uses a dual mode of action
to prevent terminal complement pathway
activation.
Front. Immunol. 14:1282155.
doi: 10.3389/fimmu.2023.1282155

COPYRIGHT
© 2023 Tang, Tang, Dhamnaskar, Hoarty,
Vyasamneni, Vadysirisack, Ma, Zhu, Wang,
Bu, Cong, Palmer, Duda, Sayegh and
Ricardo. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Guo-Qing Tang^{1*}, Yalan Tang¹, Ketki Dhamnaskar^{2†},
Michelle D. Hoarty^{3†}, Rohit Vyasamneni^{2†},
Douangson D. Vadysirisack^{3†}, Zhong Ma^{3†}, Nanqun Zhu^{3†},
Jian-Guo Wang¹, Charlie Bu¹, Bestine Cong¹, Elizabeth Palmer¹,
Petra W. Duda¹, Camil Sayegh^{3†} and Alonso Ricardo^{2†}

¹UCB Pharma, Cambridge, MA, United States, ²Ra Pharmaceuticals, Cambridge, MA, United States,
³UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States

KEYWORDS

complement activation, C5 cleavage, C5 R885 variants, C5b6, MAC formation, macrocyclic peptide inhibitor, RBC hemolysis, permeability

A corrigendum on

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

by Tang G-Q, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang J-G, Bu C, Cong B, Palmer E, Duda PW, Sayegh C and Ricardo A (2023) *Front. Immunol.* 14:1213920. doi: 10.3389/fimmu.2023.1213920

In the published article, there were errors in [Figure 3](#) as published. In part A, the binding site is the “zilucoplan binding site”, rather than the “eculizumab binding site”. In part D, “nonspecific proteinases” should be “nonspecific proteases”. The corrected [Figure 3](#) and its caption appear below.

In the published article, there was an error. The **Introduction** incorrectly states that zilucoplan is composed of a 15-amino acid macrocyclic peptide including three unnatural amino acids. Zilucoplan is composed of a 15-amino acid macrocyclic peptide including four unnatural amino acids.

A correction has been made to **Introduction**, paragraph 4. This sentence previously stated:

“It is composed of a 15-amino acid macrocyclic peptide, including three unnatural amino acids, designed to inhibit TCC activation”

The corrected sentence appears below:

“It is composed of a 15-amino acid macrocyclic peptide, including four unnatural amino acids, designed to inhibit TCC activation”

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

